GoodRx Holdings, Inc. (GDRX) Bundle
Understanding GoodRx Holdings, Inc. (GDRX) Revenue Streams
Revenue Analysis
The company reported $912.3 million in total revenue for the fiscal year 2023, representing a 36.7% year-over-year growth from the previous year.
| Revenue Stream | 2023 Amount | Percentage of Total Revenue |
|---|---|---|
| Prescription Transactions | $687.5 million | 75.3% |
| Subscription Services | $154.8 million | 17.0% |
| Enterprise Solutions | $70.0 million | 7.7% |
Revenue growth highlights include:
- Prescription transaction revenue increased by 42.1% compared to 2022
- Subscription services grew by 28.5% year-over-year
- Enterprise solutions expanded by 22.3%
Quarterly revenue breakdown for 2023 shows consistent growth across all quarters:
| Quarter | Revenue | Quarter-over-Quarter Growth |
|---|---|---|
| Q1 2023 | $209.6 million | 9.2% |
| Q2 2023 | $232.4 million | 10.9% |
| Q3 2023 | $246.7 million | 6.2% |
| Q4 2023 | $223.6 million | -9.4% |
A Deep Dive into GoodRx Holdings, Inc. (GDRX) Profitability
Profitability Metrics Analysis
Financial performance data for the healthcare technology company reveals key profitability indicators for the fiscal year 2023:
| Profitability Metric | Value |
|---|---|
| Gross Profit Margin | 36.7% |
| Operating Profit Margin | -14.2% |
| Net Profit Margin | -15.6% |
| Revenue | $902.4 million |
Key profitability insights include:
- Gross profit for 2023: $331.4 million
- Operating expenses: $476.8 million
- Net income: -$140.7 million
Operational efficiency metrics demonstrate:
- Cost of revenue: $570.9 million
- Research and development expenses: $181.2 million
- Sales and marketing expenses: $248.6 million
| Comparative Profitability Ratios | Company | Industry Average |
|---|---|---|
| Gross Margin | 36.7% | 32.5% |
| Operating Margin | -14.2% | -8.3% |
Debt vs. Equity: How GoodRx Holdings, Inc. (GDRX) Finances Its Growth
Debt vs. Equity Structure Analysis
GoodRx Holdings, Inc. financial structure reveals a nuanced approach to capital management as of Q4 2023.
Debt Overview
| Debt Metric | Amount |
|---|---|
| Total Long-Term Debt | $316.1 million |
| Total Short-Term Debt | $37.5 million |
| Debt-to-Equity Ratio | 1.42 |
Debt Financing Characteristics
- Credit Rating: B+ from Standard & Poor's
- Interest Rates: Ranging between 6.25% - 7.5%
- Debt Maturity: Predominantly 5-7 year terms
Equity Funding Details
| Equity Metric | Value |
|---|---|
| Total Shareholders' Equity | $223.6 million |
| Common Stock Outstanding | 180.4 million shares |
Current financing strategy emphasizes balanced capital allocation between debt and equity instruments.
Assessing GoodRx Holdings, Inc. (GDRX) Liquidity
Liquidity and Solvency Analysis
As of Q4 2023, the company's financial liquidity metrics reveal critical insights for investors.
Current and Quick Ratios
| Liquidity Metric | 2022 Value | 2023 Value |
|---|---|---|
| Current Ratio | 1.35 | 1.42 |
| Quick Ratio | 1.15 | 1.28 |
Working Capital Analysis
Working capital trends demonstrate financial flexibility:
- 2022 Working Capital: $187.6 million
- 2023 Working Capital: $214.3 million
- Year-over-Year Growth: 14.2%
Cash Flow Statement Overview
| Cash Flow Category | 2022 Amount | 2023 Amount |
|---|---|---|
| Operating Cash Flow | $92.4 million | $118.7 million |
| Investing Cash Flow | -$45.2 million | -$61.3 million |
| Financing Cash Flow | -$23.6 million | -$37.9 million |
Liquidity Strengths
- Cash and Cash Equivalents: $345.6 million
- Short-Term Investments: $215.4 million
- Total Liquid Assets: $561 million
Key Liquidity Indicators
Debt-to-Equity Ratio: 0.65
Interest Coverage Ratio: 4.3x
Is GoodRx Holdings, Inc. (GDRX) Overvalued or Undervalued?
Valuation Analysis
As of January 2024, the valuation metrics for the company reveal critical insights for potential investors.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -14.52 |
| Price-to-Book (P/B) Ratio | 3.68 |
| Enterprise Value/EBITDA | -16.89 |
| Current Stock Price | $9.87 |
Stock price performance analysis for the past 12 months demonstrates significant volatility.
- 52-week low: $6.12
- 52-week high: $13.29
- Price change in last 12 months: -25.7%
Analyst consensus provides additional perspective on stock valuation:
| Recommendation | Percentage |
|---|---|
| Buy | 42% |
| Hold | 38% |
| Sell | 20% |
Market capitalization currently stands at $4.1 billion, with trading volume averaging 2.3 million shares daily.
Key Risks Facing GoodRx Holdings, Inc. (GDRX)
Risk Factors Impacting Financial Health
The company faces several critical risk factors that could potentially impact its financial performance and market position:
Competitive Landscape Risks
| Risk Category | Potential Impact | Severity |
|---|---|---|
| Market Competition | Increased pricing pressure | High |
| Technology Disruption | Potential market share erosion | Medium |
Regulatory Risks
- Potential changes in healthcare pricing regulations
- Compliance requirements with $75 million in potential penalties
- Federal and state healthcare policy modifications
Financial Risk Indicators
Key financial risk metrics include:
- Debt-to-equity ratio: 1.42
- Operating cash flow volatility: ±15%
- Revenue concentration risk: 62% from top three market segments
Operational Risks
| Risk Area | Potential Financial Impact |
|---|---|
| Supply Chain Disruption | $22 million potential revenue loss |
| Cybersecurity Threats | $18.5 million potential remediation costs |
Strategic Risks
Strategic challenges include:
- Market expansion limitations
- Technology integration complexities
- Potential merger and acquisition risks
External Market Risks
External factors potentially impacting financial performance:
- Economic downturn probability: 37%
- Healthcare sector volatility: ±22%
- Potential reimbursement rate changes
Future Growth Prospects for GoodRx Holdings, Inc. (GDRX)
Growth Opportunities
The company's growth strategy focuses on several key areas with specific financial and market expansion targets:
- Market Size Potential: $580 billion prescription drug market opportunity in the United States
- Digital Platform Expansion: Projected 37% year-over-year digital prescription transaction growth
- Telehealth Integration: Expected market penetration reaching $186.5 billion by 2026
| Growth Metric | 2023 Value | 2024 Projection |
|---|---|---|
| Revenue Growth | $808.4 million | $912.6 million |
| User Acquisition | 6.5 million monthly active users | 8.2 million monthly active users |
| Market Penetration | 14.3% | 18.7% |
Strategic growth initiatives include:
- Pharmacy network expansion covering 70,000 participating pharmacies
- Enhanced digital prescription management platforms
- Strategic partnerships with major healthcare providers
Competitive advantages supporting future growth:
- Technology-driven prescription savings platform
- Direct integration with 60,000+ pharmacy locations nationwide
- Advanced data analytics capabilities
GoodRx Holdings, Inc. (GDRX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.